FDA has approved atezolizumab (Tecentriq) plus bevacizumab (Avastin) as an initial treatment for some people with advanced liver cancer. This is the first approval in 13 years for a treatment that is more effective than the current standard, sorafenib.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2XZWtpr
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2XZWtpr